News | December 14, 2023
Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Demonstrate significant bleed reduction in hemophilia A and B
Subscribe To Our Newsletter & Stay Updated
